Table 3. Analysis of variables associated with overall survival in NSCLC EGFR-mutant patients.

	Univariate			Multivariate
Predictors	HR	95% CI	P	HR	95% CI	P
Age ≥60 years	1.30	0.69–2.46	0.413	1.23	0.62–2.44	0.556
Male gender	1.05	0.61–1.82	0.849	1.04	0.54–2.02	0.907
Current/former smoker	0.98	0.53–1.80	0.940	0.93	0.44–1.97	0.844
Stage 4/recurrence	0.89	0.42–1.90	0.768	1.11	0.49–2.49	0.804
ECOG PS 3–4	1.93	1.04–3.57	0.036	1.64	0.84–3.18	0.147
Subtype of EGFR ‡
exon 19	0.63	0.36–1.10	0.107	0.82	0.44–1.50	0.515
exon 18 or 20	0.85	0.30–2.40	0.766	0.70	0.24–2.06	0.516
TKI non-response	2.74	1.52–4.94	0.001	2.74	1.43–5.24	0.002

^‡reference group was exon 21. EGFR: epidermal growth factor receptor, TKI: tyrosine kinase inhibitor, ECOG PS: eastern cooperation oncology group performance status, HR: hazard ratio, CI: confidence interval